Arrhythmias & electrophysiologyRandomised controlled trial
Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial
- Randomised controlled trial
- multicentre
- double-blind
- placebo-controlled
- 66 centres in China
Authors' conclusion
Treatment with SSYX following radiofrequency catheter ablation for persistent AF reduced the incidence of recurrent atrial tachyarrhythmias and led to clinically significant improvements in QoL during a 12-month follow-up in a Chinese population.
Study context
- Population
- Patients with persistent atrial fibrillation (AF) undergoing first catheter ablation
- Participants
- 920 patients
- Comparison
- SSYX vs placebo
- SSYXn = 460
- Placebon = 460reference
- Primary endpoint
- Recurrent atrial tachyarrhythmias lasting ≥30 s after a 3-month blanking period
- Follow-up
- 12 months
Primary result
As reported in the abstract
12-month Kaplan-Meier event-free rate from recurrent atrial tachyarrhythmias
Hazard ratio
.6
95% CI .4-.8
P = 0.001
By group
Secondary outcomes
Quality-of-life (QoL) score · 12 months
- Better QoL score with SSYX vs placebo
Safety
Serious adverse events
- No significant difference between the two groups
Original publication
Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial. Eur Heart J. Published 23 August 2024. doi:10.1093/eurheartj/ehae532
Summarised from the published abstract; every number is checked against it